Absci Corporation appointed Gerry Muhle as Chief Commercial Officer to lead commercial strategies for its ABS-201 hair regrowth treatment and broader pipeline. Muhle brings over 25 years of experience launching prescription biologics and consumer brands from companies like Galderma and Allergan. Absci aims to combine strong clinical evidence with consumer trust to build ABS-201 into a recognized brand for pattern hair loss and endometriosis treatments. Interim proof-of-concept data for ABS-201 is expected in December 2026, marking a key milestone for the company’s innovative AI-designed therapeutics.
Absci Corporation's stock is priced at USD 9.90 on Pluang, down 2.17% as of Nov 12, 2026, 19:12 WIB. The company holds a market cap of $1.73 billion and a 52-week trading range between $2.30 and $12.10. This appointment of Gerry Muhle as Chief Commercial Officer comes as Absci prepares for a key proof-of-concept milestone expected in December 2026, potentially impacting its commercial trajectory.
